The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.

被引：1
作者：
Mustacchi, Giorgio
Cazzaniga, Marina Elena
Romagnoli, Emanuela
Montemurro, Filippo
De laurentiis, Michele
Riccardi, Ferdinando
Turletti, Anna
Beano, Alessandra
De Angelis, Claudia
Graziano, Vincenzo
Livi, Lorenzo
Del Mastro, Lucia
Biganzoli, Laura
Garrone, Ornella
De Placido, Sabina
Marchetti, Paolo
Pronzato, Paolo
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study.
    Cazzaniga, Marina Elena
    Scognamiglio, Giovanni
    Generali, Daniele Giulio
    Ferzi, Antonella
    Vandone, Anna Maria
    Spadaro, Pietro
    Mocerino, Carmela
    Montagna, Emilia
    Cretella, Elisabetta
    Gambaro, Anna
    Taverniti, Cristiana
    Turletti, Anna
    Sarobba, Giuseppina
    Iezzi, Laura
    Roberto, Michela
    Ciccarese, Mariangela
    Tralongo, Paolo
    Clivio, Luca
    Pedroli, Stefania
    Torri, Valter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Lucitanib for the treatment of HR+HER2-metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial
    Hui, R.
    Pearson, A.
    Cortes Castan, J.
    Campbell, C.
    Poirot, C.
    Azim, H. A., Jr.
    Fumagalli, D.
    Lambertini, M.
    Daly, F.
    Arahmani, A.
    Perez-Garcia, J.
    Aftimos, P. G.
    Bedard, P.
    Xuereb, L.
    Loibl, S.
    Loi, S.
    Pierrat, M-J.
    Turner, N. C.
    Andre, F.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 93 - 93
  • [23] BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)
    Dalvi, T.
    Gelmon, K. A.
    Dent, R.
    Pegram, M.
    Loibl, S.
    Tazir, Y.
    Milner, A.
    Lewis, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study
    Andreis, D.
    Scandurra, G.
    Santini, D.
    Gucciardino, C.
    La Verde, N. M.
    Girelli, S.
    Alabiso, I.
    Saetta, A.
    Atzori, F.
    Collova, E.
    Ferzi, A.
    Gori, S.
    Lipari, H.
    Saggia, C.
    Marcon, I.
    Generali, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study.
    Cazzaniga, Marina Elena
    Casadei, Virginia
    Cagossi, Katia
    Cavanna, Luigi
    Cursano, Maria Concetta
    De Conciliis, Enrico Maria Romano
    Gebbia, Vittorio
    Melegari, Elisabetta
    Pellegrino, Benedetta
    Pinotti, Graziella
    Rossello, Rosalba
    Russo, Salvatore
    Ortu, Salvatore
    Saracchini, Silvana
    Stocchi, Lucia
    Toniolo, Davide
    Scognamiglio, Giovanni
    Valerio, Maria Rosaria
    Vandone, Anna Maria
    Clivio, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
  • [27] A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes
    Harbeck, N.
    Cristofanilli, M.
    Ro, J.
    Andre, F.
    Loi, S.
    Verma, S.
    Iwata, H.
    Loibl, S.
    Bartlett, C. Huang
    Zhang, K.
    Iyer, S.
    Thiele, A.
    Theall, K.
    Koehler, M.
    Turner, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S270 - S271
  • [28] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
    Anders, Carey K.
    Le Rhun, Emilie
    Bachelot, Thomas Denis
    Yardley, Denise A.
    Awada, Ahmad
    Conte, Pier Franco
    Kabos, Peter
    Bear, Melissa
    Yang, Zhengyu
    Chen, Yanyun
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Effectiveness and safety of Everolimus-Exemestane (EVE-EXE) in unselected patients (pts) with HR + /HER2-Metastatic Breast Cancer (MBC): Our experience in clinical practice
    Mafodda, A.
    Giannicola, R.
    Azzarello, D.
    Del Medico, P.
    Raffaele, M.
    Giuffre, C.
    Maisano, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): old drugs, new results. The multicenter VICTOR-6 study
    Cazzaniga, M.
    Orlando, L.
    Melegari, E.
    Arcangeli, V.
    Butera, A.
    Pinotti, G.
    Vallini, I.
    Mocerino, C.
    Giovanardi, F.
    Cretella, E.
    Gambaro, A.
    Pistelli, M.
    Donati, S.
    Pizzuti, L.
    Spagnuolo, A.
    Putzu, C.
    Leonardi, V.
    De Angelis, C.
    Pedroli, S.
    Torri, V.
    ANNALS OF ONCOLOGY, 2017, 28
12345